Life-Threatening Cryptosporidium Diarrhea in a Child on Induction Chemotherapy for Acute Lymphoblastic Leukemia

Review began 09/25/2021

Review ended 09/26/2021

Published 09/28/2021

© Copyright 2021

Bakliwal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Anamika Bakliwal¹, Uttam Kumar Nath¹, Aroop Mohanty², Pratima Gupta³

1. Medical Oncology and Haematology, All India Institute of Medical Science Rishikesh, Rishikesh, IND 2. Clinical Microbiology, All India Institute of Medical Science Gorakhpur, Gorakhpur, IND 3. Clinical Microbiology, All India Institute of Medical Science Rishikesh, Rishikesh, IND

Corresponding author: Aroop Mohanty, aroopmohanty7785@yahoo.com

Abstract

Cryptosporidium infection is usually self-limiting but can be life-threatening in immunocompromised patients. It has emerged as an important cause of diarrhea in such patients worldwide. In this report, we describe a case of Cryptosporidium diarrhea in a child on induction therapy for acute lymphoblastic leukemia (ALL); timely diagnosis using multiplex polymerase chain reaction (PCR) led to definitive treatment and a favorable outcome in our patient.

Categories: Internal Medicine, Infectious Disease, Oncology

Keywords: nitazoxanide, diarrhoea, acute lymphoblastic leukemia, multiplex pcr, cryptosporidium

Introduction

The protozoan parasite *Cryptosporidium* is recognized globally as a major cause of diarrhea in adults and children. In immunocompetent individuals, the most common manifestation is explosive watery diarrhea usually accompanied by vomiting, anorexia, cramping abdominal pain, and low-grade fever; it is usually a self-limiting illness lasting 3-14 days [1]. *Cryptosporidiosis* is a common cause of diarrhea in HIV-infected patients [2]. *Cryptosporidiosis* in immunocompromised patients is characterized by intractable watery diarrhea that is resistant to antibiotic treatment and is associated with high mortality. In this report, we present a case of life-threatening cryptosporidiosis in a severely neutropenic male child on induction chemotherapy for acute lymphoblastic leukemia (ALL), where timely diagnosis using multiplex polymerase chain reaction (PCR) of stool led to definitive treatment and a favorable outcome.

Case Presentation

A three-year-old boy undergoing induction chemotherapy for B-cell ALL in a tertiary care hospital developed acute onset of watery diarrhea and high-grade fever (103 °F) on day 19 of the induction phase. He also complained of abdominal cramps but initially, there was no blood in the stool. At the onset of diarrhea, his hemoglobin was 8.6 g/dl, total leukocyte count (TLC) was 300/μl, the absolute neutrophil count was 30/μl, and platelet count was 54,000/μl. Blood was collected under aseptic precautions in light of the fever and sent to the microbiology laboratory for culture and antibiotic sensitivity testing. Along with this, a stool sample was also sent for routine microscopic examination, culture, and modified Ziehl-Neelsen (MZN) staining to detect opportunistic pathogens. Intravenous fluids and broad-spectrum antibiotics (injection piperacillin-tazobactam and injection amikacin) were immediately started as per institutional protocol for treating a case of febrile neutropenia while waiting for the laboratory results. However, despite the antibiotic coverage, the fever persisted along with peri-anal excoriation. The daily stool frequency and volume rapidly worsened from three to four times/day (600 ml/day) to about 15-20 times/day (3.5-4 liters/day). Blood and stool cultures came out to be sterile but surprisingly, oocysts of *Cryptosporidium* were detected on MZN staining performed on smears prepared from the stool concentration method (Figure 1). Multiplex PCR of the stool specimen by BioFire® FilmArray® gastrointestinal (GI) panel (BioMerieux, Bangalore, India) was sent for confirmation and it too turned out to be positive for the presence of *Cryptosporidium* species and negative for bacterial or any other infections (Table 1).

How to cite this article

Bakliwal A, Nath U, Mohanty A, et al. (September 28, 2021) Life-Threatening Cryptosporidium Diarrhea in a Child on Induction Chemotherapy for Acute Lymphoblastic Leukemia. Cureus 13(9): e18340. DOI 10.7759/cureus.18340

PCR report	
Bacteria	
Campylobacter	Not Detected
Clostridium difficile toxin A/B	Not Detected
Plesiomonas shigelloides	Not Detected
Salmonella	Not Detected
Vibrio	Not Detected
Vibrio cholerae	Not Detected
Yersina enterocolitica	Not Detected
Diarrheagenic E. coli/shigella	
Enteraggregative E. coli (EAEC)	Not Detected
Enteropathogenic E. coli (EPEC)	Not Detected
Enterotoxigenic E. coli (ETEC) lt/st	Not Detected
Shiga-like toxin-producing E. coli (STEC) stx1/stx2	Not Detected
Shigella/Enteroinvasive E. coli (EIEC)	Not Detected
Parasites	
Giardia lamblia	Not Detected
Cryptosporidium	Detected
Entamoeba histolytica	Not Detected
Cyclospora cayetanensis	Not Detected
Viruses	
Adenovirus F 40/41	Not Detected
Astrovirus	Not Detected
Rotavirus A	Not Detected
Sapovirus	Not Detected
Norovirus GI/GII	Not Detected

TABLE 1: PCR report by BioFire® FilmArray® GI panel assay showing the detection of Cryptosporidium species

PCR: polymerase chain reaction; GI: gastrointestinal

FIGURE 1: Modified acid-fast staining showing oocysts of *Cryptosporidium* species

The patient was treated with nitazoxanide 100 mg P.O. twice daily for three days, but as there was further worsening of diarrhea, azithromycin 100 mg P.O. once daily (at 10 mg/kg body weight dose) was also added. This combination treatment was given for two weeks and it resulted in complete resolution of diarrhea 16 days after its onset. During the protracted course of symptoms, the patient also required intensive supportive treatment with intravenous fluids, broad-spectrum antibiotics, parenteral nutrition, and norepinephrine support for shock. A repeat modified acid-fast smear was prepared at the time of discharge from the hospital and it showed no *Cryptosporidium* oocysts. He had lost 30% of baseline body weight at the time of discharge from the hospital. Induction chemotherapy was restarted after the complete resolution of diarrhea and the patient achieved complete remission. There was no recurrence of *Cryptosporidiosis* in the subsequent course of treatment.

Discussion

Cryptosporidium was first identified as a cause of GI disease in humans in 1976 and is now recognized globally as an important cause of diarrhea in both children and adults [3]. It is caused by infection with oocysts of *Cryptosporidium* species and is a major cause of prolonged diarrhea in children in resource-poor countries and immunocompromised hosts [4].

Routine examination for ova and parasites usually does not detect cryptosporidia spores, and, as it cannot be cultivated in vitro, the diagnosis of *Cryptosporidium* infection is usually made by microscopic examination of stool either by using MZN acid-fast stain or an immunofluorescent assay procedure or through the use of a multiplex PCR test [5]. A number of concentration methods are available, which are laborious and used mainly in research laboratories. Many laboratories will not test for *Cryptosporidium* unless the tests are specifically requested and as a dictum, the laboratory should be alerted to the potential diagnosis of *Cryptosporidium* so that specific testing can be performed. There are several other methods like antigen detection and nucleic acid amplification. ELISA has a sensitivity of 57% and a microscopy of 45%. Hence PCR testing is increasingly being used for the diagnosis of *Cryptosporidium* and has the ability to differentiate between different *Cryptosporidium* genotypes. This test has high sensitivity compared with microscopic studies of stool, and nearly double the number of cases are diagnosed when compared with stool assays. In our patient, we used A PCR-based diagnostic tool using BioFire® FilmArray® GI panel, which has a sensitivity of 95% and a specificity of 100% when compared to routine methods to confirm the diagnosis [6]. This helped in early and prompt diagnosis, improved patient care by rapidly identifying the pathogen, and reduced morbidity and length of hospital stay.

Conclusions

The present case report emphasizes the vital diagnostic role of multiplex PCR of stool samples at the onset of diarrhea in acute leukemia patients who are often severely neutropenic and immunocompromised. This method helps in the detection of rare atypical infections like *Cryptosporidium* early in the course of illness and differentiates them from more common bacterial infections so that life-saving definitive treatment against the causative organism can be started without delay in this vulnerable population.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Lewis IJ, Hart CA, Baxby D: Diarrhoea due to *Cryptosporidium* in acute lymphoblastic leukemia . *Arch Dis Child*. 1985, 60:60-2. [10.1136/adc.60.1.60](#)
2. Kadappu KK, Nagaraja MV, Rao PV, Shastry BA: Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. *J Postgrad Med*. 2002, 48:179-81.
3. Kotloff KL, Nataro JP, Blackwelder WC, et al.: Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet*. 2013, 382:209. [10.1016/s0140-6736\(13\)60844-2](#)
4. White CA: *Cryptosporidiosis (Cryptosporidium Species)*. *Principles and Practice of Infectious Diseases*. Bennett JE, Dolin R, Blaser MJ (ed): Elsevier Saunders, Amsterdam, Netherlands; 2015. 1:3173-83.
5. Chalmers RM, Katzer F: Looking for *Cryptosporidium*: the application of advances in detection and diagnosis. *Trends Parasitol*. 2013, 29:237-51. [10.1016/j.pt.2013.03.001](#)
6. Ahmed SA, Karanis P: Comparison of current methods used to detect *Cryptosporidium* oocysts in stools . *Int J Hyg Environ Health*. 2018, 221:743-63. [10.1016/j.ijheh.2018.04.006](#)